Bayer's Balance-Sheet Momentum Builds as Japan Approves Oncology Drug and Legal Calendar Resets
Published on 08/25/2026 at 04:51 | Redaktion boerse-global.de
The third quarter is shaping up to be a defining stretch for Bayer on multiple fronts. A €3 billion capital injection from Apollo-managed funds is expected to close during the period, Japan has just cleared the company's lung cancer drug Hyrnuo for market entry, and the final approval hearing for the $7.25 billion glyphosate class-action settlement has been pushed to September 14.
That last date, rescheduled from August 19 at the joint request of Bayer and plaintiffs' attorneys, gives both sides roughly three extra weeks to process withdrawal requests on opt-out declarations and verify their validity. The delay follows a significant legal victory: in late June, the US Supreme Court ruled 7-2 in the Durnell case that federal law preempts certain state-level lawsuits over inadequate warning labels, provided the EPA has already assessed product safety. The decision is widely seen as easing a burden that has weighed on the Leverkusen-based group for years.
Debt Target Tightened After Apollo Deal
The Apollo transaction, which involves a minority stake in a newly formed entity, is the primary driver behind Bayer's revised net financial debt guidance. Management now expects year-end debt of €29 billion to €30 billion, down from the previous €32 billion to €33 billion range. The company's balance sheet has already improved considerably: net financial debt stood at €33.647 billion at the end of the second quarter.
The operational picture is more mixed. Second-quarter group revenue rose 2.2 percent to €10.872 billion, while adjusted EBITDA gained 1.9 percent to €2.144 billion. Crop Science delivered the standout performance, with revenue climbing 3.5 percent to €4.910 billion and adjusted EBITDA surging 30.2 percent to €902 million. Pharmaceuticals and Consumer Health, by contrast, grew only modestly and each saw adjusted EBITDA fall 3.6 percent.
Should investors sell immediately? Or is it worth buying Bayer?
Bottom-line figures were less flattering. Core earnings per share dropped 16.7 percent to €0.95 in the quarter, though net profit swung from minus €199 million a year earlier to plus €219 million. Free cash flow turned negative at minus €371 million, versus plus €125 million in the prior-year period, dragged down by settlement-related payments.
CEO Bill Anderson maintains the company is operationally on track to meet its full-year targets. For the first half, revenue rose 3.3 percent to €24.277 billion and core EPS climbed 3.4 percent to €3.66. The full-year outlook calls for group revenue between €44.7 billion and €46.7 billion and core EPS of €4.20 to €4.70.
Pipeline Progress and Market Response
The Hyrnuo approval in Japan adds a concrete milestone to Bayer's efforts to rejuvenate its pharma portfolio after key patent expirations. The timing is notable: management ruled out a potential split of the company just over three weeks ago, signaling a strategy centered on organic growth within individual segments rather than structural overhaul.
Shares rose 0.9 percent on Monday to €48.32 following the Japanese regulatory news. The stock has gained 5.0 percent over the past 30 days and trades roughly 18 percent above its 200-day average of €40.90, underscoring a trend that has been intact for months. At €48.33, the share price sits about 10 percent below its 52-week high of €53.86, yet remains up 31 percent year-to-date and 73 percent over twelve months.
Jefferies, which reviewed the stock after the Q2 results, maintained its "Hold" rating with a price target of €46 — a level now below the current trading price, reflecting how quickly the shares have moved.
The convergence of lower leverage, a resilient agriculture business, legal headwinds receding, and now a pharma pipeline win paints a picture of a company gradually emerging from a prolonged crisis. The negative free cash flow in the second quarter is a reminder that glyphosate-related costs will continue to shadow the financials at least until the September hearing, but the trajectory has clearly shifted.
Ad
Bayer Stock: New Analysis - 25 August
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
